Search Results 2061-2070 of 18759 for Relapse

  1. Daclizumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used ...

  2. Neurology - Clinical trials

    Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...

  3. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments - Mayo Clinic

    ... relapsed/refractory multiple myeloma (RRMM). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

  4. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

    History of second malignancy, except those treated with curative intent more than five years previously without relapse or low likelihood of recurrence (for ...

  5. Comprehensive testing leads to targeted treatment for rare autoimmune encephalitis antibody - Mayo Clinic News Network

    Spencer did have one slight relapse, which manifested as another persistent headache in January of 2022 and sent him back to an ER in the Twin Cities. An ...

  6. MAYO MAGAZINE - Autumn 2008 - MC2386-AU08

    non-Hodgkin's lymphoma who relapse following chemotherapy. “BEXXAR is an intravenous monoclonal antibody that's directed against the proteins located in ...

  7. Teriflunomide (oral route) - Side effects & dosage - Mayo Clinic

    This medicine will not cure MS, but it may slow some disabling effects and decrease the number of relapses of the disease. This medicine is available only ...

  8. Clinical trials - Oncology (Medical)

    This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...

  9. Testing The Role Of DNA Released From Tumor Cells Into The Blood In Guiding The Use Of Immunotherapy After Surgical Removal Of The Bladder, Kidney, Ureter, And Urethra For Urothelial Cancer Treatment, MODERN Study - Mayo Clinic

    ... relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment ...

  10. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

    Disease relapse during treatment or within 6 months following adjuvant therapy will be considered metastatic disease;; Patients who have received 2 prior ...